Abstract

ROGADO-VEGAS, B; SANCHEZ-GUNDIN, J; GOMEZ-GOMEZ, D  and  VALERO-DOMINGUEZ, M. Bezlotoxumab in prevention of recurrent Clostridium difficile infection. Rev. OFIL·ILAPHAR [online]. 2021, vol.31, n.1, pp.112-113.  Epub June 07, 2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x20210001000020.

Clostridium difficile (CD) is the main cause of diarrhoea associated with antibiotic use in healthcare centers and an increasingly frequent cause of community diarrhoea. One of the principal complications are recurrences, involving health and economic problems. A new strategy for the prevention of these recurrences would be the use of monoclonal antibodies as a form of passive immunity in patients with treatment for Clostridium difficile infection (CDI). Bezlotoxumab is a monoclonal antibody which acts by binding to CD toxin B and neutralize its activity. It is administered in intravenous infusion in a single dose of 10 mg/kg and always during the cycle of antibacterial treatment for the CDI. Its efficacy was demonstrated in the MODIFY I and II pivotal trials, however, there is little published real-life experience. The case of an immunosuppressed patient with multiple recurrences of diarrhea by CDI treated in a third level hospital with bezlotoxumab is presented. After one year of dose administration, the patient clinical improvement was substantial and since then the tests for CD toxin in faeces have been negative.

Keywords : Bezlotoxumab; Clostridium difficile; prevention; recurrences.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )